BS PHARM KOREA Begins Clinical Evaluation of INHILO Dual HA Skin Booster
BS PHARM KOREA has officially launched the INHILO Clinical Evaluation to objectively assess the clinical performance of INHILO Dual HA Skin Booster under standardized treatment conditions.
The clinical study is being conducted in collaboration with experienced medical professionals at DERSKIN Dermatology. It focuses on evaluating the performance of INHILO’s Hybrid HA formulation through standardized treatment and scheduled follow-up assessments.
Unlike conventional skin boosters, INHILO combines high and low molecular weight cross-linked hyaluronic acid in a single formulation. This dual molecular approach is designed to support immediate hydration while promoting long-term skin quality improvement.
Clinical Site
The INHILO Clinical Evaluation was conducted at DERSKIN Dermatology, a dermatology clinic in South Korea providing professional aesthetic and skin care treatments.
Pre-Treatment Assessment
Before treatment, all participants completed the clinical consent process and underwent a comprehensive skin assessment performed by the medical team.
Clinical Preparation
The evaluation included documentation of each participant’s baseline skin condition to enable objective comparison throughout the follow-up period.
- – Completion of clinical consent documentation
- – Baseline skin assessment
- – Individual treatment planning
- – Standardized facial photography
INHILO Clinical Evaluation Protocol
The treatment was performed according to a standardized clinical protocol to ensure consistency across all participants.
| Item | Clinical Protocol |
| Target Area | Both cheeks |
| Injection Depth | Mid-to-deep dermis |
| Total Dosage | 2.0 cc (1.0 cc per cheek) |
| Injection Technique | Micro-bolus |
| Injection Volume | 0.03–0.05 cc per point |
| Injection Pattern | 1 × 1 cm grid |
Special attention was given to maintaining accurate injection depth in the mid-to-deep dermis. Injection into the superficial dermis was avoided to minimize the risk of uneven distribution and visible skin irregularities.
Why the INHILO Clinical Evaluation Matters
Conventional non-cross-linked HA skin boosters primarily provide temporary hydration because hyaluronic acid is rapidly degraded after treatment.
In contrast, INHILO utilizes a Hybrid HA formulation that combines high and low molecular weight cross-linked HA. This technology is designed to prolong dermal hydration while supporting collagen synthesis and overall skin quality improvement.
Therefore, the INHILO Clinical Evaluation aims to generate objective clinical data on hydration durability, skin elasticity, barrier integrity, and participant satisfaction.
The Science Behind INHILO
Hybrid HA Formulation
Unlike conventional non-cross-linked HA skin boosters, INHILO utilizes a Hybrid HA matrix designed to slow natural biodegradation after injection.
This prolonged residence time may contribute to longer-lasting dermal hydration and sustained skin radiance.
Dual Molecular HA Synergy
One of the defining characteristics of INHILO is its Dual Molecular HA Technology. Instead of relying on a single molecular weight, the formulation combines high and low molecular weight cross-linked HA to maximize complementary biological functions within the dermis.
Together, these two molecular weights are designed to provide both immediate and long-term benefits.
- – High Molecular Weight HA
Delivers immediate hydration by attracting and retaining moisture within the dermis. - – Low Molecular Weight HA
Supports fibroblast activity associated with collagen and elastin synthesis. - – Combined Effect
Promotes balanced skin hydration, elasticity, and long-term skin quality improvement.
INHILO Clinical Evaluation Objectives
Throughout the follow-up period, the medical team will evaluate multiple clinical parameters using standardized observations and participant feedback. These evaluation criteria have been selected to objectively assess the overall performance of INHILO Dual HA Skin Booster.
- – Skin hydration
- – Skin elasticity
- – Skin density
- – Skin barrier integrity
- – Overall skin quality
- – Participant satisfaction
Post-Treatment Care for INHILO Clinical Evaluation
After treatment, participants received standardized post-procedure instructions designed to support recovery and maintain consistent clinical conditions throughout the evaluation period.
- – Apply cryo cooling or a soothing mask for approximately 15 minutes.
- – Avoid alcohol consumption for one week
- – Avoid smoking during the recovery period
- – Avoid saunas and steam rooms
- – Avoid excessive facial muscle activity
INHILO Clinical Evaluation Follow-Up
The INHILO Clinical Evaluation will continue through scheduled follow-up visits over the coming weeks. During each visit, the medical team will assess changes in skin hydration, elasticity, texture, and overall skin quality while documenting participant progress using standardized evaluation methods.
In addition, the study will collect participant feedback to better understand treatment satisfaction and overall clinical outcomes.
Future updates will summarize the clinical observations and overall evaluation results as the study progresses.
Conclusion
The INHILO Clinical Evaluation reflects BS PHARM KOREA’s commitment to evidence-based aesthetic innovation. Through standardized clinical assessment, the study aims to provide meaningful data that supports informed clinical decision-making for medical professionals and global business partners.
Learn More About INHILO Dual HA Skin Booster
Discover more about INHILO+, BS PHARM KOREA’s Dual HA-based aesthetic solution designed with a balanced hyaluronic acid formulation. For product details, specifications, and related information, please visit the INHILO+ product page.
Partner with BS PHARM KOREA
For business inquiries, product information, or partnership opportunities, please contact the BS PHARM KOREA team. We look forward to connecting with aesthetic professionals, distributors, and business partners worldwide
